期刊文献+

多状态Markov模型在糖尿病足研究中的应用 被引量:3

The Application of Multi-state Markov Model on Diabetic-foot Study
下载PDF
导出
摘要 目的通过建立多状态Markov模型,探讨糖尿病足各状态间转移的影响因素。方法回顾性调查98例出现糖尿病足状态转移的患者,建立多状态Markov模型,探讨影响因素。结果各因素对状态1-2的转移均无统计学意义,HDLC、本次足溃疡病程、足背动脉搏动、年龄4个因素对状态2-3的转移有统计学意义,表现为:HDLC越低、本次足溃疡病程越长、足背动脉搏动越弱、年龄越大发生状态2-3转移的风险越大。结论多状态Markov模型是探讨糖尿病足各状态间转移的影响因素的有效方法。 Objective To explore the influencing factors of stage transition of diabetic-foot by establishing the Multi-state Markov Model. Methods Retrospectively investigation was conducted among 98 patients with diabetic foot, and Multi-state Markov Model was established to explore influencing factors. Results All factors had no significant effect on the transition from stage 1 to stage 2. HDLC, disease course of diabetic-foot, pulse of dorsal artery of foot and age significantly influenced transition from stage 2 to stage 3, a lower HDLC,longer course of diabetic-foot , weaker pulse of dorsal artery of foot and older age were the main risk factors of the transition from stage 2 to stage 3. Conclusion Multi-state Markov Model was an suitable tool to explore influencing factors of stage transition of diabetic foot.
出处 《中国卫生统计》 CSCD 北大核心 2009年第3期234-236,共3页 Chinese Journal of Health Statistics
基金 卫生部临床学科重点项目
关键词 MARKOV模型 糖尿病足 自然史 Markov model Diabetic-foot Natural history
  • 相关文献

参考文献7

  • 1赵奕文,干晓燕,李家淑,刘亚宁,郑颖,唐波,王伟.彩色多普勒超声诊断糖尿病下肢中小型动脉病变的价值[J].上海医学影像,2002,11(4):282-284. 被引量:20
  • 2Mathieu E, Loup P, Dellamonica P, et al. Markov modelling of immunological and virological states in HIV-1 infected patients. Biometrical Journal,2005,47(6) :1-13.
  • 3Ricardo Ocana-Riola. Non-homogeneous markov processes for bio-medical data analysis. Biometrical Journal ,2005,47 (3) :369 - 376.
  • 4Rafael P,Juan Eloy Ruiz-Castro M. A piecewise Markov process for analysing survival from breast cancer in different risk groups. Statistics in Medicine,2001,20:109-122.
  • 5Hsieh Hsinju, Chen Tony Hsiuhsi, Chang Shuhui. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan. Statistics in Medicine ,2002,21:3369 - 3382.
  • 6Alioum Ahmadou, Commenges Daniel. MKVPCI: a computer program for Markov models with piecewise constant intensities and eovariates. Computer Methods and Programs in Biomedicine,2001,64 : 109-119.
  • 7丁园林 孔丹莉.多状态Markov模型在2型糖尿病影响因素研究中的应用[J].中国临床医药实用杂志,2003,4:276-281.

二级参考文献2

共引文献19

同被引文献38

  • 1余红梅.多状态模型简介[J].中国卫生统计,2005,22(3):177-180. 被引量:10
  • 2康殿民,王洁贞,薛付忠,王志强,王雨路.Markov模型在山东省肾综合征出血热流行趋势预测中的应用[J].现代预防医学,2006,33(9):1665-1666. 被引量:7
  • 3Juday T, Correll T, Anene A, et al. Cost-effectiveness of the once- daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US [J]. Clinicoecon Outcomes Res,2013,5:437-445.
  • 4Bonafede M, Juday T, Lenhart G, et al. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy [J]. J Med Econ, 2013,16 (4) : 552-559.
  • 5Sachs JD. Macroeconomics and health: investing in health for economic development [J]. Revista Panamericana de Salud Publica,2002,12(2) : 143-144.
  • 6Evans DB, Edejer TT-T, Adam T, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries [J]. BMJ,2005,331 (7525) : 1137-1140.
  • 7Briggs AH. Handling uncertainty in cost-effectiveness models [J]. Pharmacoeconomics,2000,17(5) :479-500.
  • 8O'Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies [J]. Pharmacoeconomics, 2005,23 (6) : 529-536.
  • 9Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents [ R ]. 2012. http://aidsinfo.nih.gov/guidelines.
  • 10Foglia E, Bonfanti P, Rizzardini G, et al. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world [J]. PLoS One, 2013, 8 (2) : e57777.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部